The use of selective serotonin reuptake The use of selective serotonin reuptake inhibitors (SSRIs) in children under 18 inhibitors (SSRIs) in children under 18 years old increased ten-fold (from 0.5 to years old increased ten-fold (from 0.5 to 4.6 per 1000) in the UK from 1992 to 4.6 per 1000) in the UK from 1992 to 2001 (Murray 2001 (Murray et al et al, 2004 . Usage rates , 2004) . Usage rates are even higher in the USA, at 16.6 per are even higher in the USA, at 16.6 per 1000 (Delate 1000 (Delate et al et al, 2004) , despite the , 2004), despite the existence of training and theoretical models existence of training and theoretical models for the treatment of mental disorders that for the treatment of mental disorders that are similar to those in the UK. Reasons are similar to those in the UK. Reasons for the increasing rates of use are likely to for the increasing rates of use are likely to include heavy promotion of both mediinclude heavy promotion of both medication and illness, distortion of the pubcation and illness, distortion of the published data related to safety and efficacy, lished data related to safety and efficacy, and underestimation by clinicians of the and underestimation by clinicians of the importance of the placebo response importance of the placebo response (Jureidini (Jureidini et al et al, 2004 (Jureidini et al et al, , 2004a . Over the past 2 ). Over the past 2 years, serious concerns have been raised years, serious concerns have been raised about the benefit-to-harm ratio of all antiabout the benefit-to-harm ratio of all antidepressants for children, leading to limits depressants for children, leading to limits on the use of some drugs and warning stateon the use of some drugs and warning statements on drug labelling. Nevertheless, a ments on drug labelling. Nevertheless, a view persists that scepticism about these view persists that scepticism about these drugs is misplaced. Unfortunately this drugs is misplaced. Unfortunately this view, which owes more to wishful thinking view, which owes more to wishful thinking than science, has permeated guidelines prothan science, has permeated guidelines produced by professional and regulatory duced by professional and regulatory authorities, particularly in the USA. On authorities, particularly in the USA. On what basis are these recommendations what basis are these recommendations being made? being made?
The evidence for efficacy has been disThe evidence for efficacy has been disappointing. At least five unpublished trials appointing. At least five unpublished trials using a placebo control have failed to show using a placebo control have failed to show an advantage for antidepressants over an advantage for antidepressants over placebo. Among eight published trials, four placebo. Among eight published trials, four found no statistically significant advantage found no statistically significant advantage for antidepressants over placebo on any for antidepressants over placebo on any primary outcome measure, and only about primary outcome measure, and only about a third (17/52) of all published measures a third (17/52) of all published measures show an advantage for drug over placebo. show an advantage for drug over placebo. Even the statistically significant improveEven the statistically significant improvements are of dubious clinical importance; ments are of dubious clinical importance; for example, Wagner for example, Wagner et al et al (2003) showed (2003) showed that the Children's Depression Rating that the Children's Depression Rating Scale -Revised (CDRS-R) score was reScale -Revised (CDRS-R) score was reduced by 22.8 points by the use of sertraduced by 22.8 points by the use of sertraline compared with 20.2 points with line compared with 20.2 points with placebo ( placebo (P P¼0.007). Thus we can have a 0.007). Thus we can have a high degree of confidence that there is an high degree of confidence that there is an extremely small, and probably clinically extremely small, and probably clinically unimportant, benefit from sertraline. It is unimportant, benefit from sertraline. It is also important to note that greater signifialso important to note that greater significance applied to adolescents rather than cance applied to adolescents rather than younger age groups, a point that was not younger age groups, a point that was not included in the abstract of the article included in the abstract of the article (Wagner (Wagner et al et al, 2003) . In discussing their , 2003). In discussing their own data, the authors of all of the four own data, the authors of all of the four positive studies exaggerated the benefits, positive studies exaggerated the benefits, downplayed the downplayed the harms, or both (Jureidini harms, or both (Jureidini et al et al, 2004 , 2004a a). The pharmaceutical industry ). The pharmaceutical industry has further distorted the literature through has further distorted the literature through suppression of data and ghost-writing of suppression of data and ghost-writing of manuscripts. The most recently published manuscripts. The most recently published study, the Treatment for Adolescents with study, the Treatment for Adolescents with Depression Study, like others before it, Depression Study, like others before it, makes claims that are not supported by makes claims that are not supported by the data published in the paper (Jureidini the data published in the paper (Jureidini et al et al, 2004 , 2004b b; Treatment for Adolescents ; Treatment for Adolescents with Depression Study Team, 2004) . In an with Depression Study Team, 2004) . In an unmasked unmasked comparison that failed to comparison that failed to account for placebo effects, expectancy account for placebo effects, expectancy effects and other non-pharmacological effects and other non-pharmacological factors, cognitive-behavioural therapy with factors, cognitive-behavioural therapy with concurrent use of fluoxetine was more concurrent use of fluoxetine was more effective than cognitive-behavioural effective than cognitive-behavioural therapy alone. The most telling finding therapy alone. The most telling finding from this study was the lack of a statistical from this study was the lack of a statistical advantage of fluoxetine over placebo in the advantage of fluoxetine over placebo in the masked masked comparison on a primary endcomparison on a primary endpoint, the CDRS-R score ( point, the CDRS-R score (P P¼0.10). This 0.10). This finding was not mentioned in the abstract finding was not mentioned in the abstract and has not been widely publicised. and has not been widely publicised.
In the absence of safety concerns even In the absence of safety concerns even small improvements might make treatment small improvements might make treatment worthwhile, but these drugs may occasionworthwhile, but these drugs may occasionally cause serious adverse outcomes. In ally cause serious adverse outcomes. In response to concerns raised about suicidal response to concerns raised about suicidal behaviour and withdrawal effects, the UK behaviour and withdrawal effects, the UK Committee on Safety of Medicines (CSM) Committee on Safety of Medicines (CSM) established an expert panel in 2002 to established an expert panel in 2002 to review paroxetine and other SSRIs. Access review paroxetine and other SSRIs. Access to all GlaxoSmithKline's trials of paroxeto all GlaxoSmithKline's trials of paroxetine therapy revealed that the unpublished tine therapy revealed that the unpublished trials in children showed increased suicide trials in children showed increased suicide risk and little evidence of efficacy. In fact, risk and little evidence of efficacy. In fact, a GlaxoSmithKline internal memorandum a GlaxoSmithKline internal memorandum showed that the company had known that showed that the company had known that their studies failed to demonstrate efficacy their studies failed to demonstrate efficacy since at least 1998. (2004) points out, a clinically significant response should be clinically significant response should be evident in a small trial, but detecting a evident in a small trial, but detecting a low-frequency event such as suicidal low-frequency event such as suicidal behaviour is difficult in clinical trials. Yet behaviour is difficult in clinical trials. Yet two independent, FDA-commissioned retwo independent, FDA-commissioned reanalyses of the trial data showed that analyses of the trial data showed that antidepressants almost doubled the risk of antidepressants almost doubled the risk of suicide-related events compared with suicide-related events compared with placebo (risk ratio 1.81, 95% CI 1.24-placebo (risk ratio 1.81, 95% CI 1.24-2.64).
2.64). In October 2004, the FDA instructed
In October 2004, the FDA instructed manufacturers to include 'black box' manufacturers to include 'black box' warnings on all antidepressants about warnings on all antidepressants about the risks of suicidal thoughts and the risks of suicidal thoughts and behaviours. behaviours.
Given that SSRIs have been marketed Given that SSRIs have been marketed for many years, one might have expected for many years, one might have expected a warning signal from post-marketing a warning signal from post-marketing surveillance and reporting systems. Unforsurveillance and reporting systems. Unfortunately post-marketing surveillance is tunately post-marketing surveillance is poorly implemented. The 'yellow card' poorly implemented. The 'yellow card' system in the UK is subject to undersystem in the UK is subject to underreporting, miscoding and flawed analyses reporting, miscoding and flawed analyses (Medawar & Herxheimer, 2003 (Medawar & Herxheimer, 2003 , ), and FDA surveillance has been weakened and FDA surveillance has been weakened by a shift of emphasis since drug companies by a shift of emphasis since drug companies began paying a premium to it in return for began paying a premium to it in return for faster drug approvals, as the events faster drug approvals, as the events surrounding the recent withdrawal of surrounding the recent withdrawal of rofecoxib demonstrate. In the case of rofecoxib demonstrate. In the case of depression and suicidality, the waters are depression and suicidality, the waters are muddied by the overlap in symptoms muddied by the overlap in symptoms between the condition and the drug, each between the condition and the drug, each of which may lead to suicidal ideation and of which may lead to suicidal ideation and behaviour, but it is safe to assume that behaviour, but it is safe to assume that there has been underestimation of the risk there has been underestimation of the risk 3 0 4 3 0 4 Psychiatrists, 2004) . The answer is probably related to how The answer is probably related to how guidelines are developed and by whom. guidelines are developed and by whom. Often the clinicians involved are those with Often the clinicians involved are those with the most experience in using particular the most experience in using particular treatments, who have frequently been treatments, who have frequently been involved in industry-supported clinical involved in industry-supported clinical trials and who have experienced success trials and who have experienced success using these drugs without always recogusing these drugs without always recognising that more than 80% of this apparent nising that more than 80% of this apparent benefit is probably related to the placebo benefit is probably related to the placebo effect. In many instances, the potential coneffect. In many instances, the potential conflicts of interest inherent in this situation flicts of interest inherent in this situation have not been addressed adequately. have not been addressed adequately.
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E D I T O R I A L E D I T O R I A L
Senior child psychiatrists warn us of the Senior child psychiatrists warn us of the 'risk of doing nothing' (Brent, 2004) , des-'risk of doing nothing' (Brent, 2004) , despite the evidence that psychotherapy has pite the evidence that psychotherapy has proved to be effective for childhood proved to be effective for childhood depression, and work by Gledhill depression, and work by Gledhill et al et al (2003) suggests that there are feasible ap- (2003) suggests that there are feasible approaches for general practitioners to use proaches for general practitioners to use in milder cases that involve neither drugs in milder cases that involve neither drugs nor formal cognitive-behavioural therapy. nor formal cognitive-behavioural therapy. Further, few children prescribed antidepresFurther, few children prescribed antidepressants persist with treatment for more than 2 sants persist with treatment for more than 2 months (Shireman months (Shireman et al et al, 2002; Murray , 2002; Murray et et al al, 2004) , suggesting that the therapeutic , 2004), suggesting that the therapeutic benefits may not be sufficient to outweigh benefits may not be sufficient to outweigh disadvantages in the view of the child or disadvantages in the view of the child or parent. It seems that, given the perceived parent. It seems that, given the perceived need to 'do something' and the wishful need to 'do something' and the wishful thinking that the drugs may actually be thinking that the drugs may actually be better than the trial evidence indicates, the better than the trial evidence indicates, the injunction to 'first do no harm' has been injunction to 'first do no harm' has been forgotten. forgotten.
The currently available evidence indiThe currently available evidence indicates that the SSRIs should not be cates that the SSRIs should not be recommended as first-line treatment in chilrecommended as first-line treatment in children with depression. We are concerned dren with depression. We are concerned that regulators and writers of clinical guidethat regulators and writers of clinical guidelines worldwide will not grasp this nettle, lines worldwide will not grasp this nettle, particularly given the potential conflicts of particularly given the potential conflicts of interest of those who are also investigators interest of those who are also investigators in clinical trials. We are encouraged by in clinical trials. We are encouraged by the draft guidelines issued on its website the draft guidelines issued on its website , and hope that its final recommendations will not be marred by wishful tions will not be marred by wishful thinking. thinking.
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